Capmatinib price

Introduction: from Laos Lucius Pharmaceuticals has a specification of 200mg per tablet, 60 tablets per box, and the price is roughly between 2650$ and 2800$. This price range provides patients with a relatively economical option, especially compared to some other versions of the drug. Drug prices may fluctuate due to market supply and demand, so patients should understand the latest price information before purchasing and make purchasing decisions carefully. At the same time, there are potential risks for any behavior of purchasing medicines without the guidance of a doctor. Therefore, patients are recommended to consult a professional doctor before purchasing medicines.

Capmatinib

Capmatinib (capmatinib) is an oral small molecule inhibitor of cell-mesenchymal epithelial transition factor (c-Met). It was researched by Incyte and developed by Novartis Pharmaceuticals. It was approved by the US FDA in May 2020 under the trade name Tabrecta. Capmatinib is indicated for the treatment of adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations.

Efficacy of capmatinib

As a highly efficient MET1b inhibitor, capmatinib has shown significant efficacy in the treatment of patients with METex14 advanced NSCLC. Clinical data shows that for patients who are newly treated, the objective effective rate is as high as 68%, and for patients who have received pre-treatment, the effective rate is also as high as 41%. This achievement provides new treatment options for patients with advanced NSCLC and is expected to improve patients' survival conditions and quality of life. However, patients still need to strictly follow medical instructions, pay attention to possible side effects, and undergo regular review and evaluation when receiving capmatinib treatment.

Capmatinib price and purchase

Capmatinib from Lucius Pharmaceuticals in Laos is 200 mg per tablet, 60 tablets per box, and the price is about $2650 to $2800. Although this drug has not yet been introduced in China, patients can still purchase it through domestic and overseas medical service institutions, or go abroad to purchase it on their own. Capmatinib, as a highly efficient and highly selective MET1b inhibitor, has significant efficacy in patients with METex14 advanced NSCLC. When purchasing and using drugs, patients should ensure that the drugs come from regular sources and follow medical instructions to ensure that the drugs are safe and effective.